Mati Gill is the CEO of AOIN Labs, a first-of-its-kind AI venture studio built on the Israeli innovation ecosystem and backed by global pharma and technology leaders, with a mission to build and grow groundbreaking AI companies in biopharma—bringing together brilliant minds, pharma expertise, and cutting-edge technology to shape the future of drug discovery and development.
Before leading AOIN Labs, Mati built a career spanning public service, legal management, and operational leadership—serving as a minister's bureau chief in the Israeli government, then spending over a decade at Teva Pharmaceuticals rising from legal intern to global legal COO to the architect of Teva's external innovation program, where he made an early bet on AI and machine learning in Israeli R&D before most of the industry knew why.
At AOIN Labs, Mati leads a model of company creation that combines pre-seed funding, pharma partner validation, and a pre-committed proof-of-concept framework that removes the risk killing most early-stage AI biotech companies before they get traction. With partners including Teva, Pfizer, AstraZeneca, Merck, and Amazon Web Services, Mati's journey from American-born kid who moved reluctantly to Jerusalem at twelve, to IDF officer, to lawyer-turned-government-official, to pharma executive turned venture studio founder shows what it looks like when someone spends a career building exactly the skills their mission will one day require.
.png)